Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as xaliproden (SR57746A)
xaliproden · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Xaliproden (SR57746A) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Xaliproden (SR57746A) | DRUG | oral administration |
| Placebo | DRUG | oral administration |
| Oxaliplatin | DRUG | IV administration |
| 5-Fluorouracil | DRUG | IV administration |
| Leucovorin | DRUG | IV administration |
Inclusion Criteria: Main inclusion criteria : * Histologically or cytologically-proven metastatic cancer of the colon or rectum. * Metastatic disease not amenable to potentially curative treatment (eg: inoperable metastatic disease). * Male or female aged \>18 years. * WHO Performance Status (PS) ...
Top 20 of 30 competitors
Xaliproden has been studied in two main areas: Alzheimer disease and the prevention of chemotherapy-induced neurotoxicity in patients with metastatic colorectal cancer. It is an investigational small molecule that has not been approved for any indication. Clinical development reached Phase 3, and all reported trials have been completed.
Xaliproden targets the serotonin 1A receptor, also known as HTR1A, where it acts as an agonist. This receptor activity is the basis for its investigation in neurological and chemotherapy-related nerve toxicity settings. The drug is a small molecule developed by Sanofi.
Xaliproden is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 clinical program evaluating the drug in Alzheimer disease and in patients receiving oxaliplatin-based chemotherapy for metastatic colorectal cancer.
Xaliproden reached Phase 3 clinical development. All three reported trials are completed, and no trials are currently active. The drug remains investigational and has not been approved by the FDA for any indication.
Xaliproden has been evaluated in three completed Phase 3 trials: NCT00305188 in metastatic colorectal cancer, NCT00104013 in mild-to-moderate Alzheimer disease, and NCT00103649, an 18-month Alzheimer disease study. Together these trials enrolled more than 3,600 participants across North America, Europe, Asia, South America, and Australia.
Yes, xaliproden is also known as SR57746A. SR57746A is the compound code used by Sanofi in trial titles and publications, while xaliproden is the international nonproprietary name. Both names refer to the same investigational small-molecule HTR1A agonist.